Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

andesbio.com

Founded Year

2008

Stage

Seed VC | Alive

Total Raised

$2.17M

Last Raised

$2.17M | 5 yrs ago

About Andes Biotechnologies Global

Andes Biotechnologies is a nucleic acid-based drug discovery and Development Company focused on solid tumor cancers. The company has discovered two novel families of long noncoding RNAs: sense (S-RNA) and antisense noncoding (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus. The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide therapeutics that target the novel long noncoding regulatory RNA that is present in a variety of cancer indications.

Andes Biotechnologies Global Headquarters Location

Parque Tecnológico Zañartu Av. Zañartu 1482, Ñuñoa

Santiago,

Chile

+56 22 367 2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Andes Biotechnologies Global

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Andes Biotechnologies Global is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

838 items

Andes Biotechnologies Global Patents

Andes Biotechnologies Global has filed 6 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Oncology
  • Alkylating antineoplastic agents
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/17/2019

5/3/2022

Antineoplastic drugs, Transcription factors, Experimental cancer drugs, Alkylating antineoplastic agents, Oncology

Grant

Application Date

9/17/2019

Grant Date

5/3/2022

Title

Related Topics

Antineoplastic drugs, Transcription factors, Experimental cancer drugs, Alkylating antineoplastic agents, Oncology

Status

Grant

Andes Biotechnologies Global Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Andes Biotechnologies Global Rank

  • When was Andes Biotechnologies Global founded?

    Andes Biotechnologies Global was founded in 2008.

  • Where is Andes Biotechnologies Global's headquarters?

    Andes Biotechnologies Global's headquarters is located at Parque Tecnológico Zañartu, Santiago.

  • What is Andes Biotechnologies Global's latest funding round?

    Andes Biotechnologies Global's latest funding round is Seed VC.

  • How much did Andes Biotechnologies Global raise?

    Andes Biotechnologies Global raised a total of $2.17M.

  • Who are the investors of Andes Biotechnologies Global?

    Investors of Andes Biotechnologies Global include Austral Capital and Aurus Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.